Clinical study of pemetrexed-based chemotherapy in the treatment of elderly patients with advanced non-squamous non-small-cell lung cancer
10.3760/cma.j.issn.1006-9801.2014.02.003
- VernacularTitle:以培美曲塞为基础的联合化疗方案治疗老年人晚期非鳞非小细胞肺癌的临床研究
- Author:
Haiyuan XU
;
Liqiang WANG
;
Lina ZHOU
;
Zhangyi JI
;
Minbin CHEN
- Publication Type:Journal Article
- Keywords:
Carcinoma,non-small-cell lung;
Non-squamous cell carcinoma;
Pemetrexed;
Cisplatin;
Carboplatin;
Aged
- From:
Cancer Research and Clinic
2014;26(2):80-83,86
- CountryChina
- Language:Chinese
-
Abstract:
Objective To assess the clinical efficacy and adverse effect of pemetrexed-based chemotherapy as first-line treatment in elderly patients with advanced non-squamous non-small-cell lung cancer (NSCLC).Methods A total of 40 elderly patients with advanced non-squamous NSCLC confirmed by pathology were retrospective analyzed in the study,who received pemetrexed plus cisplatin (group A,n =18) or pemetrexed plus carboplatin (group B,n =22) as the first-line treatment.RECIST was used to assess the efficacy of the treatment and NCI-CTC AE version was used to describe adverse events.Results In the 40 patients,no one received complete response (CR),17 patients showed partial response (PR),16 had stable disease (SD),7 had progress disease (PD),the objective response rate (ORR) was 42.5 ％ (17/40) and the disease control rate (DCR) was 82.5 ％ (33/40).The median progression-free survival (PFS) time was 5.3 months.1 year suvival rate was 63.2 ％ (24/38).In further subgroup analyses,the ORR,DCR,PFS and 1 year suvival rate in group A were higher than those in group B,but they had no statistically significant difference (P ＞ 0.05).The drug-related adverse events were myelosuppression,gastrointestinal response,most of which were grade 1 to 2.Conclusion Pemetrexed combined with cisplatin or carboplatin may be recommended as first-line chemotherapy for elderly patients with advanced non-squamous NSCLC because of its safety and efficacy.
